Attached files
file | filename |
---|---|
8-K - FORM 8-K - Bausch Health Companies Inc. | a58204e8vk.htm |
EX-10.1 - EX-10.1 - Bausch Health Companies Inc. | a58204exv10w1.htm |
EX-10.2 - EX-10.2 - Bausch Health Companies Inc. | a58204exv10w2.htm |
Exhibit 99.1
International Headquarters
7150 Mississauga Road
Mississauga, Ontario L5N 8M5
Phone: 905.286.3000
Fax: 905.286.3050
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Laurie W. Little
949-461-6002
laurie.little@valeant.com
VALEANT PHARMACEUTICALS APPOINTS
PHILIP W. LOBERG AS INTERIM CFO
PHILIP W. LOBERG AS INTERIM CFO
Mississauga, Ontario, December 20, 2010 Valeant Pharmaceuticals International, Inc. (NYSE:
VRX) (TSX: VRX) today announced that Philip W. Loberg, Valeants former senior vice president and
corporate controller, has been named to the role of interim chief financial officer, effective
immediately, replacing Peggy Mulligan, former chief financial officer, who has elected to resign
in order to pursue other interests. The Company has initiated a search to identify a permanent
replacement.
The Board of Directors and I appreciate the contributions Peggy has made during these past
few months involving the successful integration activities between Valeant and Biovail and we wish
her well in her future endeavors, said J. Michael Pearson, chief executive officer. Phil has
been an integral part of the Valeant finance department for over 10 years and played key roles in
the successful integration of over eighteen acquisitions and several debt financings. Under Phils
direction, Valeant implemented a turnaround strategy which included strengthening our financial
systems and establishing strict internal controls at our various business units. I am confident
that our financial organization will operate seamlessly during this transition process.
Philip W. Loberg joined Valeant in 2000 as treasurer and was appointed chief financial officer
of North America in 2006. In 2007, he was appointed to his most recent role of senior vice
president, group financial controller, and in that role, Mr. Loberg has been responsible for the
upgrading and retooling of the global finance department following restructurings and the
disposition of non-performing assets. In addition, Mr. Loberg simplified and streamlined the SEC
compliance and reporting process and was instrumental in the integration of multiple new businesses
throughout the global enterprise. Prior to joining Valeant, Mr. Loberg was the vice president,
controller at Calcomp Technology, Inc., a publically traded, majority-owned subsidiary of Lockheed
Martin Corporation, and was acting chief financial officer early in his tenure. Mr. Loberg
graduated with a bachelors of science degree from the University of Southern California and
completed his CPA exam in 1984.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
More information about Valeant can be found at www.valeant.com.
Forward looking statements
This press release may contain forward-looking statements, including, but not limited to,
statements regarding the successful integration of Valeant and Biovail and the ability of the
financial organization to operate seamlessly during this transition process. Forward-looking
statements may be identified by the use of the words anticipates, expects, intends, plans,
should, could, would, may, will, believes, estimates, potential, or continue and
variations or similar expressions. These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. These risks
and uncertainties include, but are not limited to, risks and uncertainties discussed in the
companys most recent annual or quarterly report filed with the Securities and Exchange Commission
(SEC) and other risks and uncertainties detailed from time to time in the Companys filings with
the SEC and the Canadian Securities Administrators (CSA), which factors are incorporated herein
by reference. Readers are cautioned not to place undue reliance on any of these forward-looking
statements. Valeant undertakes no obligation to update any of these forward-looking statements to
reflect events or circumstances after the date of this press release or to reflect actual outcomes.
###